The Latest Analyst Ratings For Janux Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 9 analysts have evaluated Janux Therapeutics (NASDAQ:JANX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 68.44% to $68.22. Recent analyst actions include rating adjustments and price target changes, reflecting varied sentiments about the company's future performance.
May 30, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed views on Janux Therapeutics, with a recent increase in the average 12-month price target to $68.22. The company has received a mix of bullish and somewhat bullish ratings, reflecting varied sentiments about its future performance.
The increase in the average 12-month price target and the majority of bullish ratings suggest a positive short-term outlook for Janux Therapeutics. The varied sentiments among analysts indicate some uncertainty, but the overall trend is upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100